Clinical Trials Logo

Clinical Trial Summary

Patients with unexplained stress dyspnea ( ≥ stage 2 NYHA), no significant underlying lung disease, with an ejection fraction > 50%, normal resting filling pressures, NTproBNP < 220 pg/ml in < 75 years, and < 450 pg/ml in ≥ 75 years will be studied with stress echocardiography and cardiometabolic stress test (VO2). These patients may have abnormal adaptation during exercise, suggesting that chronic symptoms may be related to a heart failure with preserved ejection fraction (HFPEF). More accurate and earlier diagnosis of HFPEF using stress echocardiography and VO2 may better manage stress dyspnea in patients and prevent progression of HFPEF.

A clinical assessment will be offered to people with unexplained stress dyspnea. The procedures and products used in this study are usually used as part of HFpEF's diagnostic strategy. During this assessment, carried out on an outpatient basis, an anamnesis collection, a cardiovascular clinical examination, an evaluation of dyspnea by the NYHA functional class and by 2 questionnaires, an electrocardiogram will be carried out, a 6-minute walk test, a biological blood test, a trans thoracic rest and stress cardiac ultrasound, respiratory functional tests (with diffusion capacity of lung for carbon monoxide (DLCO) and blood gas), and a metabolic stress test. A follow-up at 1 and 2 years is planned (visit, sampling and resting echocardiography).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03550235
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Emmanuelle BERTHELOT, Dr
Phone 33145213735
Email emmanuelle.berthelot@aphp.Fr
Status Recruiting
Phase
Start date October 8, 2018
Completion date November 2021

See also
  Status Clinical Trial Phase
Recruiting NCT01618981 - LEft Atrial Pacing in Diastolic Heart Failure N/A
Completed NCT01726049 - Sildenafil in HFpEF and PH Phase 3
Completed NCT01185067 - Physiological Effects of Grape Seed Extract in Diastolic Heart Failure Phase 1
Completed NCT01091467 - Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction
Recruiting NCT03254485 - A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Phase 2
Recruiting NCT02901184 - Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction Phase 4
Recruiting NCT01288365 - The Impact of Exercise Training on Functional Capacity in Heart Failure N/A
Recruiting NCT03506412 - Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction Phase 4
Active, not recruiting NCT02078947 - Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure N/A
Withdrawn NCT03340233 - Understanding the Mechanisms of Diastolic Dysfunction N/A
Recruiting NCT03226652 - Heart Function in Patients Assessed for Sleep Apnoea
Active, not recruiting NCT01030991 - Classification of Heart Failure With Preserved Ejection Fraction
Completed NCT01411735 - Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure Phase 3
Active, not recruiting NCT01920711 - Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction Phase 3
Recruiting NCT03617848 - Optimising Management of Patients With Heart Failure With Preserved Ejection Fraction in Primary Care
Withdrawn NCT03160625 - Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF N/A
Recruiting NCT02053246 - Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure Phase 4
Terminated NCT00840463 - Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan Phase 4
Completed NCT00207220 - Ventricular-Vascular Coupling in Heart Failure N/A
Enrolling by invitation NCT03351179 - Predictors and Outcomes of In-hospital HFpEF in AMI Patients N/A